Perosphere Inc. Receives FDA IND Clearance to Initiate Clinical Investigations of the Safety and Efficacy of PER977 to Reverse the Activity of Anticoagulation Therapies Including Factor Xa- and IIa-Inhibitors
5/22/2013 11:07:24 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MOUNT KISCO, N.Y.--(BUSINESS WIRE)--Perosphere Inc. announced today that it has received U.S. Food and Drug Administration ("FDA") Investigational New Drug ("IND") clearance to initiate clinical investigations of the safety and efficacy of PER977 to reverse the anticoagulant activity of unfractionated heparin, low molecular weight heparins, fondaparinux, and factor Xa- and IIa-inhibitors. PER977 has demonstrated the ability to reverse the anticoagulant effects of unfractionated heparin, low molecular weight heparins, fondaparinux, and factor Xa- and IIa-inhibitors in vitro in animal models and ex vivo in human blood.
Help employers find you! Check out all the jobs and post your resume.
comments powered by